Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seeking the ideal antihypertensive therapy in obesity-related hypertension
2016-000571-25Phase 4Active
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olmesartan in hypertension (HTN) (4 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: median systolic and diastolic arterial pressure over 24 hours. Started Apr 2016; status: active.
02
Drugs
olmesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2016-000571-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000571-25.